Antiangiogenic therapy for breast cancer with triple negative phenotype

Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inna P. Ganshina, Kristina A. Ivanova, Olga O. Gordeeva, Aleksandr V. Arkhipov, Liudmila G. Zhukova
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	triple-negative breast cancer angiogenesis bevacizumab antiangiogenic therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cb366314608049f6bfa9212ee32b672e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb366314608049f6bfa9212ee32b672e
record_format	dspace
spelling	oai:doaj.org-article:cb366314608049f6bfa9212ee32b672e2021-11-30T16:55:00ZAntiangiogenic therapy for breast cancer with triple negative phenotype1815-14341815-144210.26442/18151434.2021.1.200763https://doaj.org/article/cb366314608049f6bfa9212ee32b672e2021-05-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/70338/51272https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we successfully use targeted drugs (antiestrogens and anti-HER-2 drugs), for triple-negative breast cancer we have not had such targets for a long time. Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies. One of the approaches in the treatment of malignant tumors includes not the impact on tumor cells, but the process of angiogenesis. Antiangiogenic drugs have positively proven themselves in the treatment of a large number of malignant tumors but are underestimated for breast cancer (including triple-negative phenotype). The use of bevacizumab in combinations with cytostatic drugs in breast cancer therapy (including triple-negative breast cancer) has been studied in a large number of clinical trials but was undeservedly forgotten in some countries due to the revoked FDA registration. This review presents the role of bevacizumab in the treatment of patients with triple-negative breast cancer and suggests the conditions when the administration of this drug is justified and leads to better results.Inna P. GanshinaKristina A. IvanovaOlga O. GordeevaAleksandr V. ArkhipovLiudmila G. ZhukovaIP Habib O.N.articletriple-negative breast cancerangiogenesisbevacizumabantiangiogenic therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 1, Pp 88-92 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	triple-negative breast cancer angiogenesis bevacizumab antiangiogenic therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	triple-negative breast cancer angiogenesis bevacizumab antiangiogenic therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Inna P. Ganshina Kristina A. Ivanova Olga O. Gordeeva Aleksandr V. Arkhipov Liudmila G. Zhukova Antiangiogenic therapy for breast cancer with triple negative phenotype
description	Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we successfully use targeted drugs (antiestrogens and anti-HER-2 drugs), for triple-negative breast cancer we have not had such targets for a long time. Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies. One of the approaches in the treatment of malignant tumors includes not the impact on tumor cells, but the process of angiogenesis. Antiangiogenic drugs have positively proven themselves in the treatment of a large number of malignant tumors but are underestimated for breast cancer (including triple-negative phenotype). The use of bevacizumab in combinations with cytostatic drugs in breast cancer therapy (including triple-negative breast cancer) has been studied in a large number of clinical trials but was undeservedly forgotten in some countries due to the revoked FDA registration. This review presents the role of bevacizumab in the treatment of patients with triple-negative breast cancer and suggests the conditions when the administration of this drug is justified and leads to better results.
format	article
author	Inna P. Ganshina Kristina A. Ivanova Olga O. Gordeeva Aleksandr V. Arkhipov Liudmila G. Zhukova
author_facet	Inna P. Ganshina Kristina A. Ivanova Olga O. Gordeeva Aleksandr V. Arkhipov Liudmila G. Zhukova
author_sort	Inna P. Ganshina
title	Antiangiogenic therapy for breast cancer with triple negative phenotype
title_short	Antiangiogenic therapy for breast cancer with triple negative phenotype
title_full	Antiangiogenic therapy for breast cancer with triple negative phenotype
title_fullStr	Antiangiogenic therapy for breast cancer with triple negative phenotype
title_full_unstemmed	Antiangiogenic therapy for breast cancer with triple negative phenotype
title_sort	antiangiogenic therapy for breast cancer with triple negative phenotype
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/cb366314608049f6bfa9212ee32b672e
work_keys_str_mv	AT innapganshina antiangiogenictherapyforbreastcancerwithtriplenegativephenotype AT kristinaaivanova antiangiogenictherapyforbreastcancerwithtriplenegativephenotype AT olgaogordeeva antiangiogenictherapyforbreastcancerwithtriplenegativephenotype AT aleksandrvarkhipov antiangiogenictherapyforbreastcancerwithtriplenegativephenotype AT liudmilagzhukova antiangiogenictherapyforbreastcancerwithtriplenegativephenotype
_version_	1718406472275066880

Antiangiogenic therapy for breast cancer with triple negative phenotype

Ejemplares similares